Picture supply: Getty Photos
I nonetheless bear in mind the primary time I began investing in FTSE shares over a decade in the past. Largely as a result of my first £1,000 funding was an amazing success, greater than doubling in worth within the area of some months, permitting me to purchase my first automotive.
However the reminiscence can also be vivid for one more cause: I mistook luck for talent, and proceeded to make some horrible, misguided selections that despatched me again to sq. one.
Must you purchase OXB shares at present?
Earlier than you determine, please take a second to evaluation this report first. Regardless of ongoing uncertainties from Trump’s tariffs to world conflicts, Mark Rogers and his group consider many UK shares nonetheless commerce at substantial reductions, providing savvy traders loads of potential alternatives to study.
That is why this might be a super time to safe this precious analysis – Mark’s analysts have scoured the markets to disclose 5 of his favorite long-term ‘Buys’. Please, do not make any large selections earlier than seeing them.
What occurred?
Wanting again, this ‘due diligence’ was hardly as much as par. And I had no clue in regards to the risks of investing in younger biotech companies – this might be related once more in a second.
Thankfully, my funding proved to be near-perfect timing. Just a few months later, OXB’s LentiVector platform proved to be a large success, enabling administration to safe a landmark industrial cope with Novartis. The outcome? OXB shares surged from round 100p per share to over 600p on a split-adjusted foundation.
So what did I do with all my winnings (past shopping for a pink second-hand Renault Clio)? I, in fact, piled every part into one other younger early-stage biotech enterprise referred to as ValiRx.
After 12 months, I misplaced nearly 90%, at which level I bought my shares in dismay and determined perhaps I wasn’t Warren Buffett in spite of everything. And by the way in which, ValiRx shares are nonetheless down 99.9% at present.
Classes realized
The obvious lesson isn’t to put money into a dangerous biotech group with no income, no merchandise, and big capital expenditures forward. However the extra precious educating is to recognise and perceive why OXB succeeded the place ValiRx failed.
OXB, whereas nonetheless dangerous, had a singular product that enormous biotech teams’ analysis cell therapies desperately wanted. This offered a precious and highly effective moat to the agency that has since propelled it from a tiny penny inventory to a £775m enterprise at present.
Having realised this, I ultimately invested in OXB once more in 2018. And alongside different extra clever and knowledgeable funding selections, I recovered from my losses and have since propelled my wealth to unbelievable highs.
Is OXB nonetheless a purchase in 2026?
Right now, OXB focuses nearly completely on its LentiVector platform as a gene remedy contract growth and manufacturing organisation. In easy phrases, it helps different biotech firms develop and manufacture their very own remedies.
The transfer massively de-risked the enterprise, since OXB’s success not is determined by profitable and costly medical trials, it will get paid both method. And since viral vector manufacturing is awfully advanced, the corporate continues to profit from the benefit that kicked off its journey – monumental limitations to entry.
However whereas cell and gene remedy is a structural megatrend throughout the biotech sector, it’s necessary to not understate the dangers. OXB’s nonetheless unprofitable, its income’s depending on a small variety of main pharmaceutical shoppers, and the steadiness sheet’s began accumulating important debt.
So is OXB a promising FTSE development share alternative in 2026? Sure. Is it dangerous? Completely. That’s why I’ve solely allotted 1.5% of my portfolio to the enterprise.
